by 
Human immunoglobulin (pH4) for intravenous injection is a blood protein collected from human blood plasma that helps strengthen the body’s immune system. It is utilized for the treatment and prevention of various primary immunodeficiency diseases. Human immunoglobulin is used for the treatments of certain neurological disorders like Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). It works by replacing missing or non-working antibodies and stopping inflammatory processes in the body.
The global human immunoglobulin (pH4) for intravenous injection market is estimated to be valued at US$ 12 billion in 2023 and is expected to exhibit a CAGR of 16.% over the forecast period 2023-2033, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increased Demand for Treatments of Neurological Disorders: As mentioned in the heading, the growing prevalence of neurological disorders like Guillain-Barré syndrome and CIDP is a major factor fueling the demand for human immunoglobulin (pH4) for intravenous injection. According to some estimates, around 1 to 2 people per 100,000 are affected by Guillain-Barré syndrome each year globally. This rising incidence rate of neurological conditions is boosting the adoption of immunoglobulin therapies as an effective treatment option.
Expanding Applications: Extensive research and clinical trials have demonstrated the effectiveness of human immunoglobulin in treating various other rare immunological and inflammatory disorders including Stevens-Johnson syndrome, toxic epidermal necrolysis, Kawasaki disease, and pediatric HIV infection. The ability of immunoglobulin to be used for broad range of applications beyond primary immunodeficiency diseases is further propelling the overall market growth.
Segment Analysis
The global human immunoglobulin (pH4) for intravenous injection market is dominated by the liquid sub-segment. The liquid sub-segment holds over 80% market share due to its ease of administration. The liquid form of immunoglobulin can be directly administered through intravenous injection. This sub-segment is expected to continue its dominance during the forecast period.
PEST Analysis
Political: Regulatory bodies like FDA closely monitor the supply and production of immunoglobulin products. Any changes in regulations can impact the market dynamics.
Economic: Rising disposable incomes in developing countries is positively impacting the spending on essential medical products and supporting the market growth.
Social: Growing cases of primary immunodeficiency diseases and rising awareness about its treatment options is driving more patients to seek immunoglobulin therapy.
Technological: Continuous focus on developing better purification techniques is helping improve the safety and efficacy of immunoglobulin products. Advanced production facilities are also increasing the supply capabilities.
Key Takeaways
The global human immunoglobulin (pH4) for intravenous injection market is expected to witness high growth driven by rising incidence of autoimmune and primary immunodeficiency disorders.
North America holds over 40% value share backed by growing healthcare expenditure and high diagnosis rates. The U.S. is the major revenue generator due to strong demand for immunoglobulin therapies. Europe also captures a sizable market value share with countries like Germany and the U.K. being major revenue pockets.
Key players operating in the human immunoglobulin (pH4) for intravenous injection market are Octapharma, CSL Behring, GT Biologics, China Biologics Products Holdings, Biotest, Kedrion, and Grifols S.A. Octapharma leads the market owing to its robust portfolio of immunoglobulin products and global footprint.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
